CS and malaria: In a previous controlled human malaria infection study in malaria-naive adults, an Fx017 regimen led to increased anti-CS antibody avidity when compared with an R012 regimen [10, 25], although in a second controlled human malaria infection study, no difference was observed between protected and unprotected individuals [9].